Antoine Adenis


Ontology type: schema:Person     


Person Info

NAME

Antoine

SURNAME

Adenis

Publications in SciGraph latest 50 shown

  • 2018-12 Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial in BMC CANCER
  • 2018-12 The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers in BMC CANCER
  • 2018-12 Predictors of abnormal cytology among HPV-infected women in remote territories of French Guiana in BMC WOMEN'S HEALTH
  • 2018-12 Illegal gold miners in French Guiana: a neglected population with poor health in BMC PUBLIC HEALTH
  • 2018-12 Temporal trend of the proportion of patients presenting with advanced HIV in French Guiana: stuck on the asymptote? in BMC RESEARCH NOTES
  • 2018-01 Predictors of complications of snake envenomation in Cayenne, French Guiana, 2007–2015 in INTENSIVE CARE MEDICINE
  • 2017-12 The singular epidemiology of HPV infection among French Guianese women with normal cytology in BMC PUBLIC HEALTH
  • 2017-12 Cutaneous leishmaniasis in French Guiana: revising epidemiology with PCR-RFLP in TROPICAL MEDICINE AND HEALTH
  • 2017-10-24 Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib in BRITISH JOURNAL OF CANCER
  • 2017-01 Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2016-12 Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program in BMC CANCER
  • 2016-12 Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program in BMC CANCER
  • 2016-12 Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin—folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial in BMC CANCER
  • 2016-12 Prevalence of Plasmodium spp. in illegal gold miners in French Guiana in 2015: a hidden but critical malaria reservoir in MALARIA JOURNAL
  • 2016-06 Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue in PHARMACEUTICAL MEDICINE
  • 2015-12 Screening for cervical cancer in French Guiana: screening rates from 2006 to 2011 in BULLETIN DE LA SOCIÉTÉ DE PATHOLOGIE EXOTIQUE
  • 2015-12 Prevalence and predictive factors for renouncing medical care in poor populations of Cayenne, French Guiana in BMC HEALTH SERVICES RESEARCH
  • 2014-12 Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group in BMC CANCER
  • 2014-12 The off-label use of targeted therapies in sarcomas: the OUTC’S program in BMC CANCER
  • 2014-06 Histoplasmosis in HIV-Infected Patients: A Review of New Developments and Remaining Gaps in CURRENT TROPICAL MEDICINE REPORTS
  • 2014-03 Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial in BRITISH JOURNAL OF CANCER
  • 2013-12 Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking in RADIATION ONCOLOGY
  • 2013-12 Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications in TARGETED ONCOLOGY
  • 2013-12 Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas – PRODIGE 19 – FFCD1103 – ADCI002 in BMC CANCER
  • 2013-12 Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome in BMC CANCER
  • 2013-11 A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours in BRITISH JOURNAL OF CANCER
  • 2012-12 Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors in MEDICAL ONCOLOGY
  • 2012-07 Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study in BRITISH JOURNAL OF CANCER
  • 2012-05 Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib in ANNALS OF SURGICAL ONCOLOGY
  • 2012-04 Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials in INVESTIGATIONAL NEW DRUGS
  • 2011-12 Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial in BMC CANCER
  • 2011-12 Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs in INVESTIGATIONAL NEW DRUGS
  • 2011-12 Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival in RADIATION ONCOLOGY
  • 2011-12 The role of El Niño southern oscillation (ENSO) on variations of monthly Plasmodium falciparum malaria cases at the cayenne general hospital, 1996-2009, French Guiana in MALARIA JOURNAL
  • 2011-10 A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens in INVESTIGATIONAL NEW DRUGS
  • 2010-12 Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials in INVESTIGATIONAL NEW DRUGS
  • 2010-10 Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer in BRITISH JOURNAL OF CANCER
  • 2010-08 Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients in INVESTIGATIONAL NEW DRUGS
  • 2010-04 Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care in BRITISH JOURNAL OF CANCER
  • 2010-04 Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis in INVESTIGATIONAL NEW DRUGS
  • 2010-02 Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics in INVESTIGATIONAL NEW DRUGS
  • 2010-01 Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer in BRITISH JOURNAL OF CANCER
  • 2010-01 Actualité sur la chirurgie robotique du cancer du rectum in ONCOLOGIE
  • 2009-08 Cancer-associated hypercalcemia: validation of a bedside prognostic score in SUPPORTIVE CARE IN CANCER
  • 2009-06 Publication biases and phase II trials investigating anticancer targeted therapies in INVESTIGATIONAL NEW DRUGS
  • 2008-04 Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis in SUPPORTIVE CARE IN CANCER
  • 2008-04 Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C in QUALITY OF LIFE RESEARCH
  • 2007-12 Angiosarcomas and Taxanes in CURRENT TREATMENT OPTIONS IN ONCOLOGY
  • 2006-09 Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial in BRITISH JOURNAL OF CANCER
  • 2001 Carcinoma of the colon in BRITISH JOURNAL OF CANCER
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.452351.4", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416188.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412451.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418191.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412212.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418037.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.476460.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417520.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.29172.3f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411349.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416200.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.121334.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418680.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.440366.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410463.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418189.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.460797.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413104.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.461714.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410527.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417666.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.16149.3b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418116.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.39009.33", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.14925.3b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418443.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412180.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411266.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413303.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418936.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418525.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.429536.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.484651.a", 
            "type": "Organization"
          }
        ], 
        "familyName": "Adenis", 
        "givenName": "Antoine", 
        "id": "sg:person.01303404424.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303404424.36"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:56", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_647.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01303404424.36'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01303404424.36'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01303404424.36'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01303404424.36'


     

    This table displays all metadata directly associated to this object as RDF triples.

    80 TRIPLES      10 PREDICATES      43 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01303404424.36 schema:affiliation N62b00c5f0f2b4e8eaf1768d512bcb4f0
    2 https://www.grid.ac/institutes/grid.121334.6
    3 https://www.grid.ac/institutes/grid.14925.3b
    4 https://www.grid.ac/institutes/grid.16149.3b
    5 https://www.grid.ac/institutes/grid.29172.3f
    6 https://www.grid.ac/institutes/grid.39009.33
    7 https://www.grid.ac/institutes/grid.410463.4
    8 https://www.grid.ac/institutes/grid.410527.5
    9 https://www.grid.ac/institutes/grid.411266.6
    10 https://www.grid.ac/institutes/grid.411349.a
    11 https://www.grid.ac/institutes/grid.412180.e
    12 https://www.grid.ac/institutes/grid.412212.6
    13 https://www.grid.ac/institutes/grid.412451.7
    14 https://www.grid.ac/institutes/grid.413104.3
    15 https://www.grid.ac/institutes/grid.413303.6
    16 https://www.grid.ac/institutes/grid.416188.2
    17 https://www.grid.ac/institutes/grid.416200.1
    18 https://www.grid.ac/institutes/grid.417520.5
    19 https://www.grid.ac/institutes/grid.417666.4
    20 https://www.grid.ac/institutes/grid.418037.9
    21 https://www.grid.ac/institutes/grid.418116.b
    22 https://www.grid.ac/institutes/grid.418189.d
    23 https://www.grid.ac/institutes/grid.418191.4
    24 https://www.grid.ac/institutes/grid.418443.e
    25 https://www.grid.ac/institutes/grid.418525.f
    26 https://www.grid.ac/institutes/grid.418680.3
    27 https://www.grid.ac/institutes/grid.418936.1
    28 https://www.grid.ac/institutes/grid.429536.f
    29 https://www.grid.ac/institutes/grid.440366.3
    30 https://www.grid.ac/institutes/grid.460797.b
    31 https://www.grid.ac/institutes/grid.461714.1
    32 https://www.grid.ac/institutes/grid.476460.7
    33 https://www.grid.ac/institutes/grid.484651.a
    34 schema:familyName Adenis
    35 schema:givenName Antoine
    36 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303404424.36
    37 schema:sdDatePublished 2019-03-07T14:56
    38 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    39 schema:sdPublisher N7645a902fef84ad08329e27e25cba823
    40 sgo:license sg:explorer/license/
    41 sgo:sdDataset persons
    42 rdf:type schema:Person
    43 N62b00c5f0f2b4e8eaf1768d512bcb4f0 schema:affiliation https://www.grid.ac/institutes/grid.452351.4
    44 sgo:isCurrent true
    45 rdf:type schema:OrganizationRole
    46 N7645a902fef84ad08329e27e25cba823 schema:name Springer Nature - SN SciGraph project
    47 rdf:type schema:Organization
    48 https://www.grid.ac/institutes/grid.121334.6 schema:Organization
    49 https://www.grid.ac/institutes/grid.14925.3b schema:Organization
    50 https://www.grid.ac/institutes/grid.16149.3b schema:Organization
    51 https://www.grid.ac/institutes/grid.29172.3f schema:Organization
    52 https://www.grid.ac/institutes/grid.39009.33 schema:Organization
    53 https://www.grid.ac/institutes/grid.410463.4 schema:Organization
    54 https://www.grid.ac/institutes/grid.410527.5 schema:Organization
    55 https://www.grid.ac/institutes/grid.411266.6 schema:Organization
    56 https://www.grid.ac/institutes/grid.411349.a schema:Organization
    57 https://www.grid.ac/institutes/grid.412180.e schema:Organization
    58 https://www.grid.ac/institutes/grid.412212.6 schema:Organization
    59 https://www.grid.ac/institutes/grid.412451.7 schema:Organization
    60 https://www.grid.ac/institutes/grid.413104.3 schema:Organization
    61 https://www.grid.ac/institutes/grid.413303.6 schema:Organization
    62 https://www.grid.ac/institutes/grid.416188.2 schema:Organization
    63 https://www.grid.ac/institutes/grid.416200.1 schema:Organization
    64 https://www.grid.ac/institutes/grid.417520.5 schema:Organization
    65 https://www.grid.ac/institutes/grid.417666.4 schema:Organization
    66 https://www.grid.ac/institutes/grid.418037.9 schema:Organization
    67 https://www.grid.ac/institutes/grid.418116.b schema:Organization
    68 https://www.grid.ac/institutes/grid.418189.d schema:Organization
    69 https://www.grid.ac/institutes/grid.418191.4 schema:Organization
    70 https://www.grid.ac/institutes/grid.418443.e schema:Organization
    71 https://www.grid.ac/institutes/grid.418525.f schema:Organization
    72 https://www.grid.ac/institutes/grid.418680.3 schema:Organization
    73 https://www.grid.ac/institutes/grid.418936.1 schema:Organization
    74 https://www.grid.ac/institutes/grid.429536.f schema:Organization
    75 https://www.grid.ac/institutes/grid.440366.3 schema:Organization
    76 https://www.grid.ac/institutes/grid.452351.4 schema:Organization
    77 https://www.grid.ac/institutes/grid.460797.b schema:Organization
    78 https://www.grid.ac/institutes/grid.461714.1 schema:Organization
    79 https://www.grid.ac/institutes/grid.476460.7 schema:Organization
    80 https://www.grid.ac/institutes/grid.484651.a schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...